Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-32766D and PD-32766T in Relapsed or Refractory Clear Cell Renal Cell Carcinoma
NCT07688187Phase 1Recruiting
- Sponsor
- PeptiDream Inc.
- Start
- Jul 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of PD-32766T in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by PeptiDream Inc. Primary endpoints: Dose-Limiting Toxicities at 6 weeks, Adverse Events at 6 months and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
PD-32766T
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07688187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688187.